EUVIMEDEUVIMED entdecken
Crossref

Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for In Vivo Theranostics of Alzheimer’s Disease

Lei Wang, Tianyu Sun, Tengfei Zhen, Wei Li iD, Huajing Yang, Suyu Wang, Feng Feng, Yao Chen, Haopeng Sun iD

Journal of Medicinal Chemistry · 25.04.2024 · 67 (8) · 6793-6809

DOI: 10.1021/acs.jmedchem.4c00355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.03.2024. Verfasst von Lei Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China. Hauptthemen laut MEDLINE: Alzheimer Disease, Butyrylcholinesterase, Fluorescent Dyes, Cholinesterase Inhibitors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Qinglan Project of Jiangsu Province of China, ?333 Project? of Jiangsu Province, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Butyrylcholinesterase (BChE) is a promising biomarker and effective therapeutic target for Alzheimer's disease (AD). Herein, we designed a BChE-activated near-infrared (NIR) probe, DTNP, which could be activated by BChE and inhibit its enzymatic activity. DTNP is composed of a cyclopropane moiety as the recognition unit, a NIR fluorophore hemicyanine as the NIR reporter, and a BChE inhibitor as the therapeutic unit. DTNP specifically binds BChE with high sensitivity and exhibits strong "turn-on" NIR fluorescence as well as nerve cell protection. In vivo imaging shows DTNP has favorable blood-brain barrier permeability and long-term tracking ability with preliminary competence in AD diagnosis. DTNP can significantly inhibit BChE activity, promote the release of ACh, and rescue learning deficits and cognitive impairment. Therefore, DTNP, the first reported and partially validated theranostic probe for the detection of BChE in AD, may provide a foundation and inspiration for imaging and therapy in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseButyrylcholinesteraseFluorescent DyesCholinesterase InhibitorsAnimalsHumansMiceTheranostic NanomedicineBlood-Brain BarrierMaleOptical Imaging

Substanzen

ButyrylcholinesteraseFluorescent DyesCholinesterase Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People's Republic of China.
  • School of Pharmacy, Nanjing Medical University, Nanjing 211166, People's Republic of China.

ORCID-Profile: Wei Li, Haopeng Sun

Förderung

  • Qinglan Project of Jiangsu Province of China
  • ?333 Project? of Jiangsu Province
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Wang, L., Sun, T., Zhen, T., Li, W., Yang, H., Wang, S., Feng, F., Chen, Y., & Sun, H. (2024). Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for In Vivo Theranostics of Alzheimer’s Disease. Journal of Medicinal Chemistry, 67(8), 6793-6809. https://doi.org/10.1021/acs.jmedchem.4c00355

Vancouver

Wang L, Sun T, Zhen T, Li W, Yang H, Wang S, et al. Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for In Vivo Theranostics of Alzheimer’s Disease. Journal of Medicinal Chemistry. 2024;67(8):6793-6809. doi:10.1021/acs.jmedchem.4c00355

BibTeX
@article{Wang2024,
  author = {Wang, Lei and Sun, Tianyu and Zhen, Tengfei and Li, Wei and Yang, Huajing and Wang, Suyu and Feng, Feng and Chen, Yao and Sun, Haopeng},
  title = {Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for In Vivo Theranostics of Alzheimer’s Disease},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {8},
  pages = {6793--6809},
  doi = {10.1021/acs.jmedchem.4c00355}
}
Kostenlos starten →